Cellular therapies, in which living cells are the drug administered to patients, have the potential to advance treatment for a variety of inherited and acquired diseases. CyteQuest is addressing the need for a flexible electroporation platform that can facilitate discovery and easily scale cell therapy manufacturing from the research level (low-volume) to the clinical level (high-volume). With our approach, a researcher can optimize transfections 50X faster than conventional cuvette systems, using small volumes of precious cells to rapidly explore a range of chemical and electrical conditions. Once identified, these parameters would be used for large-scale clinical manufacturing of cells without costly re-optimization. Our platform dramatically reduces the time and cost to develop and manufacture cell therapies. This will expand the availability of cell therapies to treat a wider range of diseases, extending treatment to a much broader patient community.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
Electroporation instruments for flexible multiplexed Optimization (low-volume) and Manufacturing (high-volume) of cellular therapies
Development Phase of Primary Product:
Discovery
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
